Pancreatic Cancer Research

ResearcherBC Cancer AgencyActive in the last 2 years

Kasmintan A. Schrader

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7413-4314; OpenAlex author ID A5024943747, A5063747371, A5160275172. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
55
Papers, trials and grants by year

2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. Parent-of-Origin-Aware Genomic Analysis to Enhance Cascade Testing in Pancreatic Cancer: A Population-Based Study Last author DOI 10.64898/2026.10.30.26366356↗
  2. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  3. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  4. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  5. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  6. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  7. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Last author DOI 10.1002/cam4.2973↗
  8. Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. Last author DOI 10.1101/mcs.a003681↗
  9. CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome. Last author DOI 10.1186/s13053-018-0088-y↗
  10. Temporal Dynamics of Genomic Alterations in a BRCA1 Germline-Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorour… Co-author DOI 10.1200/po.18.00057↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David F. Schaeffer · 5 shared papers, 2018–2026 · strength 0.48
  2. Daniel John Renouf · 5 shared papers, 2018–2026 · strength 0.48
  3. Carol Cremin · 4 shared papers, 2018–2026 · strength 0.41
  4. Jessica N. Everett · 3 shared papers, 2021–2024 · strength 0.33
  5. Aaron J. Grossberg · 3 shared papers, 2021–2024 · strength 0.33
  6. James M. Lindberg · 3 shared papers, 2021–2024 · strength 0.33
  7. Bryson W. Katona · 3 shared papers, 2021–2024 · strength 0.33
  8. Diane M. Simeone · 3 shared papers, 2021–2024 · strength 0.33
  9. Teresa A. Brentnall · 3 shared papers, 2021–2024 · strength 0.33
  10. Andrew M. Lowy · 3 shared papers, 2021–2024 · strength 0.33
  11. Sonia S. Kupfer · 3 shared papers, 2021–2024 · strength 0.33
  12. Aimee Lee Lucas · 3 shared papers, 2021–2024 · strength 0.33
  13. Salvatore Paiella · 3 shared papers, 2021–2024 · strength 0.33
  14. Daniel C. Chung · 3 shared papers, 2021–2024 · strength 0.33
  15. Yan Bi · 3 shared papers, 2021–2024 · strength 0.33
  16. George Zogopoulos · 3 shared papers, 2021–2024 · strength 0.33
  17. Jennifer B. Permuth · 3 shared papers, 2021–2024 · strength 0.33
  18. Fay Kastrinos · 3 shared papers, 2021–2024 · strength 0.33
  19. Raymond Couric Wadlow · 2 shared papers, 2023–2024 · strength 0.25
  20. Randall E. Brand · 2 shared papers, 2023–2024 · strength 0.25
  21. James J. Farrell · 2 shared papers, 2023–2024 · strength 0.25
  22. Elena M. Stoffel · 2 shared papers, 2023–2024 · strength 0.25
  23. Julie Earl · 2 shared papers, 2023–2024 · strength 0.25
  24. Talia Golan · 2 shared papers, 2021–2024 · strength 0.21
  25. Joy Liau · 2 shared papers, 2021–2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.